Lymphoma is one of the hematologic malignancies that occur at a higher rate in human
immunodeficiency virus-infected individuals. It is one of the most frequent neoplastic causes …

Primary effusion lymphoma (PEL) is a rare B-cell malignancy that most often occurs in
immunocompromised patients, such as HIV-infected individuals and patients receiving …

Patients infected with human immunodeficiency virus (HIV) are at increased risk for
develo** both non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). Even if this …

Primary effusion lymphoma (PEL) is an aggressive type of non-Hodgkin lymphoma localized
predominantly in body cavities. Kaposi's sarcoma-associated herpes virus (KSHV) is the …

Primary effusion lymphoma (PEL) is a rare and aggressive B-cell non-Hodgkin's lymphoma
that usually presents with malignant effusions without tumor masses. An extracavitary or …

Simple Summary Epstein–Barr virus (EBV) is involved in lymphomagenesis, especially
lymphomas affecting populations with immunodeficiencies, such as people living with HIV …

Selenium compounds such as methylseleninic acid (MSA) and sodium selenite (SS) have
been widely evaluated as potential anti-cancer agents in the clinical setting. Primary effusion …

Using records from the National Cancer Data Base, we studied overall survival of CD20-
negative variants of diffuse large B-cell lymphoma (DLBCL): primary effusion (PEL, N= 228) …

Primary effusion lymphoma (PEL) is a rare and an aggressive B‐cell non‐Hodgkin
lymphoma with a distinctive clinicobiological features. As a result of the rarity of this …

Pomalidomide (Pom) is an immunomodulatory drug that has efficacy against Kaposi's
sarcoma, a tumor caused by Kaposi's sarcoma-associated herpesvirus (KSHV). Pom also …